Drug price negotiations for the new acute myelogenous leukemia drug Xospata, which aims to be exempted, have passed the year.

Astellas Korea and the NHIS conducted drug price negotiations until the 20th to register insurance benefits for Acute Myeloid Leukemia (AML), but decided to extend the negotiation deadline without reaching a conclusion.

After receiving a conditional benefit decision by the HIRA's Drug Benefit Evaluation Committee in September, the proposed evaluation amount was accepted and drug price negotiations began in November, but failed to conclude negotiations within the first deadline.

As a result, it remains to be seen whether Xospata will be able to comple